SCHEMBL13617393

SCHEMBL13617393

NC(=O)c1ccc(-c2ncccn2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 8/20 0.62
MKNK2 Q9HBH9 8/20 0.62
MAP4K4 O95819 2/20 0.57
RIPK1 Q13546 1/20 0.53
CAMKK2 Q96RR4 1/20 0.53
CYP2C19 P33261 2/20 0.50
HSD17B10 Q99714 2/20 0.50
POLB P06746 1/20 0.50
CYP3A4 P08684 1/20 0.50
PARP1 P09874 1/20 0.50
MAPT P10636 1/20 0.50
TSHR P16473 1/20 0.50
RECQL P46063 1/20 0.50
BLM P54132 1/20 0.50
PMP22 Q01453 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
ADRB2 P07550 1/20 0.50
CYP17A1 P05093 1/20 0.50
CHEK2 O96017 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4927431 0.80 CHEK2 (0.67) MKNK1MKNK2MAP4K4CYP2C19HSD17B10
SCHEMBL1222172 0.80 MKNK1 (0.55) MKNK1MKNK2CAMKK2TSHRKDM4E
SCHEMBL15748062 0.79 MKNK1 (0.53) MKNK1MKNK2MAP4K4CYP2C19HSD17B10
SCHEMBL13389553 0.79 CLK4 (0.42) MKNK1MKNK2MAP4K4RIPK1CAMKK2
SCHEMBL27631215 0.78 WDR5 (0.59) HSD17B10RECQLBLMTDP1ADRB2
SCHEMBL3553363 0.78 CLK4 (0.45) MKNK1MKNK2MAP4K4CYP3A4ADRB2
SCHEMBL17758807 0.78 MAPT (0.59) MAP4K4MAPTL3MBTL1ADRB2NPC1
SCHEMBL1002578 0.78 CA2 (0.67) MKNK1MKNK2MAP4K4CYP2C19HSD17B10
SCHEMBL6685962 0.78 CLK4 (0.64) HSD17B10POLBCYP3A4MAPTBLM
SCHEMBL4631461 0.78 PRKCI (0.54) PARP1CHEK2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4559902-A2 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE Imago Biosciences Inc. (US) 2025-05-28 EP disclosed
EP-3256218-B1 A KDM1A INHIBITOR AND ITS USE IN THERAPY IMAGO BIOSCIENCES INC (US) 2024-12-11 EP disclosed
US-11773068-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2023-10-03 US disclosed
US-20220073477-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2022-03-10 US disclosed
US-11230534-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2022-01-25 US disclosed
WO-2009133831-A1 PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF 旭化成ファーマ株式会社 (JP) 2009-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11230534-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A MKNK1 897/4885MKNK2 894/4885MAP4K4 2120/4885
US-20220073477-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A MKNK1 897/4885MKNK2 894/4885MAP4K4 2120/4885
US-11773068-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A MKNK1 897/4885MKNK2 894/4885MAP4K4 2120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.